Bausch + Lomb Corporation

BLCO

Equity

ISIN CA0717051076 / Valor 116024614

New York Stock Exchange, Inc (2024-09-18)

USD 20.00+7.76%

Bausch + Lomb Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Bausch + Lomb Corporation is a diversified healthcare company that focuses on ophthalmic products and services. The company has a strong presence in the surgical business unit, specializing in cataract, refractive, and vitreoretinal surgery. Bausch + Lomb also offers a wide range of ophthalmic pharmaceuticals, contact lenses, eye drops, and healthcare products for both humans and animals. With a history of strategic acquisitions and product launches, Bausch + Lomb continues to expand its product portfolio and maintain a leading position in the eye care industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Bausch + Lomb Corporation reported total revenue of $1.099 billion for the first quarter of 2024, an increase of $168 million or 18% compared to the first quarter of 2023. Excluding the unfavorable impact of foreign exchange, revenue increased by approximately 20% on a constant currency basis.

Vision Care Segment

The Vision Care segment of Bausch + Lomb Corporation generated $635 million in revenue for the first quarter of 2024, up from $587 million in the first quarter of 2023. This represents an increase of $48 million or 8%, with a constant currency growth rate of approximately 11% driven by products like Daily SiHy lenses and LUMIFY®.

Surgical Segment

For the first quarter of 2024, the Surgical segment revenue was $197 million, compared to $183 million in the first quarter of 2023. This marks an increase of $14 million or 8%, with constant currency growth also at 8%, driven by growth in consumables, implantables, and equipment.

Pharmaceuticals Segment

The Pharmaceuticals segment saw a significant revenue increase to $267 million for the first quarter of 2024, up from $161 million in the first quarter of 2023. This represents a growth of $106 million or 66%, primarily due to the acquisition of XIIDRA and strong launch performance of MIEBO.

Net Loss

Bausch + Lomb Corporation reported a net loss of $167 million for the first quarter of 2024, compared to a net loss of $90 million for the first quarter of 2023. The increase in net loss was primarily due to higher interest expenses and tax provisions, partially offset by improved operating results.

Summarized from source with an LLMView Source

Key figures

13.4%1Y

%3Y

%5Y

Performance

36.4%1Y

39.0%3Y

39.0%5Y

Volatility